We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00403039
First Posted: November 23, 2006
Last Update Posted: January 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Vitreous -Retina- Macula Consultants of New York
  Purpose
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema

Condition Intervention Phase
Retinal Vein Occlusion Drug: Ranibizumab (Lucentis ) Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Intravitreally Administered Ranibizumab in 20 Subjects With Macular Edema Associated With CRVO.

Resource links provided by NLM:


Further study details as provided by Vitreous -Retina- Macula Consultants of New York:

Primary Outcome Measures:
  • To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of Macular Edema associated with CRVO [ Time Frame: 72 months ]

Secondary Outcome Measures:
  • Proportion of patients losing ≤ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 3, 6, 12, 24, 36, 48, 60 and 72 [ Time Frame: Months 3, 6, 12, 24, 36, 48, 60 and 72 ]
  • Proportion of patients gaining ≥ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 3, 6, 12, 24, 36, 48, 60 and 72. [ Time Frame: Months 3, 6, 12, 24, 36, 48, 60 and 72 ]
  • Change in central retinal thickness as measured by OCT at months 3, 6, 9, 12, 24, 36, 48, 60 and 72 compared to baseline [ Time Frame: Months 3, 6, 12, 24, 36, 48, 60 and 72 ]
  • Proportion of subjects losing ≥ 30 letters as measured by ETDRS visual refraction at month 6, 12, 24, 36, 48, 60 and 72 [ Time Frame: Months 6, 12, 24, 36, 48, 60 and 72 ]

Enrollment: 41
Study Start Date: November 2006
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Open-label ranibizumab
Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
Drug: Ranibizumab (Lucentis )

Detailed Description:
This is an open-label, Phase I study of intravitreally administered ranibizumab in 20 subjects with macular edema associated with CRVO. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 ± 2 days for a total of 3 injections. Thereafter they are to be evaluated every month until month 12. If the patients have signs of increased intraretinal hemorrhage or a persistence / increase in central macular edema as determined by optical coherence tomography when compared to their last visit, are eligible for re-injection at that monthly visit.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Clinical evidence of perfused central retinal vein occlusion. A central retinal vein occlusion (CRVO) is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head. .
  • Central macular edema present on clinical examination and OCT testing with a central point thickness > 250 microns
  • Visual acuity score greater than or equal to 34 letters (20/200) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
  • Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography

Exclusion Criteria:

  • Pregnancy (positive pregnancy test) or known to be pregnant, also premenopausal women not using adequate contraception.
  • Participation in another simultaneous ocular investigation or trial
  • Patient with uncontrolled hypertension
  • Patient has a condition that, in the opinion of the investigator would preclude participation in the study (i.e. chronic alcoholism, drug abuse)
  • Patient has significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
  • Exam or OCT reveals evidence of vitreoretinal interface abnormality that may be contributing to the macular edema
  • Eye that in the investigator has no chance of improvement in visual acuity following resolution of macular edema (i.e subretinal fibrosis or geographic atrophy)
  • Any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), age related macular degeneration (AMD), retinal detachment, severe cataracts, etc.
  • Evidence of neovascularization of the iris or retina (presence of ischemic CRVO)
  • History of Grid/Focal laser or Panretinal laser in the study eye
  • History of vitreous surgery in the study eye
  • History of use of intravitreal, peribulbar, or retrobulbar steroids within six months of the study.
  • History of Cataract Surgery within 6 months of enrollment.
  • History of YAG capsulotomy within 2 months of the surgery.
  • Visual acuity <20/400 in the fellow eye
  • Uncontrolled Glaucoma, pressure >30 despite treatment with glaucoma medications.
  • Use of Bevacizumab in either eye within the past 30 days
  • Use of Pegaptinib sodium in either eye within the past 6 weeks
  • Use of Triamcinolone in either eye
  • Have received any other systemic experimental drug within 12 weeks prior to enrollment.
  • Unwilling or unable to follow or comply with all study related procedures.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00403039


Locations
United States, New York
Vitreous Retina Macula Consultants of New York, P.C.
New York City, New York, United States, 10022
Sponsors and Collaborators
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.
Investigators
Principal Investigator: Richard F. Spaide, M.D. Vitreous Retina Macula Consultants of New York, P.C.
  More Information

Responsible Party: Vitreous -Retina- Macula Consultants of New York
ClinicalTrials.gov Identifier: NCT00403039     History of Changes
Other Study ID Numbers: FVF3851S
First Submitted: November 22, 2006
First Posted: November 23, 2006
Last Update Posted: January 1, 2016
Last Verified: December 2015

Keywords provided by Vitreous -Retina- Macula Consultants of New York:
Central Retinal Vein Occlusion

Additional relevant MeSH terms:
Macular Edema
Retinal Vein Occlusion
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Ranibizumab
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents